Acutaas Chemicals Limited (ACUTAAS): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Acutaas Chemicals Limited, explained in plain English.
- Acutaas Chemicals Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- ACUTAAS closed at ₹3,833.50 on 20 November 2026.
- Over the past year the shares are up 121.3%, trading between ₹1,570.00 and ₹4,130.00.
- Reported fundamentals show return on equity of 26.11%, a net margin of 27.58%, debt to equity of 0.79.
- Our Pulse grade checklist scores it A (96/100) across momentum, growth, profitability and safety on fixed thresholds.
- Annualised volatility over the past year is 45.83% with a maximum drawdown of -17.53% and a beta of 0.69 against NIFTY 50.
- Recent coverage: Angel One flags breakout on Acutaas, Indus Towers and one more stock
- Recent coverage: Nifty IT’s 18% rally may mark a durable leadership cycle; 35,000 next: LKP's Vatsal Bhuva
Other Pharma & Healthcare companies: Abbott India, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon
Last traded values from 20 Nov 2026. Market closed.
Pharma & Healthcare · Specialty Chemicals
Acutaas Chemicals Limited (ACUTAAS)
₹3,991.3
▲ 48.4 (+1.23%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 5/51M
+24.49%
3M
+17.69%
6M
+42.59%
1Y
+132.86%
Where it sits in its 52-week range
98%Below 52-week high
1.2%
149.1% above the low
Momentum read
Strong
5/5 checks passed
52-wk high
₹4,039.1
52-wk low
₹1,602.5
Market cap
₹32,677 Cr
P/E (trailing)
74.7
Dividend yield
—
ROE
26.11%
Profit margin
27.58%
Revenue growth
42.7%
Price / Book
17.59
Debt / Equity
0.79
EPS (TTM)
53.42
Book value
₹226.9
Beta
0.68
Pulse grade: A, 96 out of 100
Momentum
A- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✓Positive 3-month return
Growth
A- ✓Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
A- ✓Return on equity above Pharma & Healthcare median (14.56%)
- ✓Return on equity above 12%
- ✓Profit margin above Pharma & Healthcare median (13.82%)
Safety
A- ✓Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹437 crore · net profit ₹125 crore · margin 28.6%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
ACUTAAS headlines
No ACUTAAS stories right now.
ACUTAAS filings & announcements
ACUTAAS, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
46.72%
Sharpe ratio
1.89
Sortino ratio
3.11
Max drawdown
-17.53%
Daily VaR (95%)
-3.99%
CAGR (1Y)
131.16%
Return skew
0.41
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.